🏆 Top Bodybuilding SARMS Ranked by What they do, Potency & Effectiveness
You can Scroll right for additional Data
| SARM | Category | Half-Life | Dose (mg/day) | Goal | Muscle Gain | Fat Loss | Admin | Aromatization | Notes | Power Rating (1–10) |
|---|---|---|---|---|---|---|---|---|---|---|
| S-40503 | Bone Health | ~8–10 h | 10–25 | Bone Density | Low | None | Oral | None | Focuses on preventing osteoporosis. | 4 |
| LGD-3303 | Bulking | ~6–8 h | 5–15 | Bulking | High | Low | Oral | None | Potent anabolic with dry gains, early research stage. | 8 |
| Ligandrol (LGD-4033) | Bulking | ~24–36 h | 5–10 | Bulking | High | Low | Oral | None | Potent mass builder, suppressive at higher doses. | 9 |
| RAD-150 | Bulking | ~48 h | 10–20 | Bulking | High | Moderate | Oral | None | Esterified RAD-140, longer lasting, anabolic. | 9 |
| Testolone (RAD-140) | Bulking | ~16–20 h | 10–20 | Bulking | Very High | Moderate | Oral | None | One of the most anabolic SARMs, may impact testosterone levels. | 10 |
| RAD-1901 (Elacestrant) | Cancer Research | ~40 h | 10–20 | Medical | None | None | Oral | None | Selective estrogen receptor degrader (SERD). | 2 |
| Andarine (S4) | Cutting | ~4–6 h | 25–50 | Cutting | Moderate | High | Oral | None | Drying effect, may cause temporary night vision issues. | 7 |
| GW-501516 (Cardarine) | Endurance | ~24 h | 10–20 | Fat Loss | None | High | Oral | None | PPAR agonist, not a true SARM, boosts endurance/fat burn. | 6 |
| SR9009 | Fat Loss | ~2 h | 20–30 | Fat Loss | Low | High | Oral | None | REV-ERB agonist, boosts metabolism, enhances endurance. | 6 |
| SR9011 | Fat Loss | ~2 h | 20–40 | Fat Loss | Low | High | Oral | None | Similar to SR9009, also boosts stamina. | 6 |
| Stenabolic (SR9009) | Fat Loss | ~2 h | 20–30 | Cutting | Low | High | Oral | None | Increases metabolic activity without affecting the CNS. | 6 |
| MK-677 (Ibutamoren) | GH Secretagogue | ~24 h | 10–25 | Bulking | Moderate | Moderate | Oral | None | Not a true SARM, raises GH and IGF-1, increases hunger. | 8 |
| S23 | Hardening | ~12 h | 10–30 | Recomp | High | High | Oral | None | Very suppressive, used with testosterone base in stacks. | 9 |
| Ostarine (MK-2866) | Muscle Preservation | ~24 h | 10–30 | Recomp | Moderate | Moderate | Oral | None | Mild and well-tolerated, good for beginners and cuts. | 7 |
| GLPG-0492 | Muscle Wasting | ~12 h | 10–30 | Recomp | Moderate | Moderate | Oral | None | Being studied for Duchenne muscular dystrophy. | 6 |
| GLPG0492 | Muscle Wasting | ~12 h | 10–30 | Recomp | Moderate | Low | Oral | None | Developed for Duchenne muscular dystrophy. | 6 |
| GSK2881078 | Muscle Wasting | ~6–8 h | 10–30 | Recomp | Moderate | Low | Oral | None | In clinical trials for sarcopenia. | 7 |
| GSX-007 | Muscle Wasting | ~8–10 h | 10–25 | Recomp | Moderate | Low | Oral | None | Aimed at treating age-related muscle decline. | 6 |
| GTX-024 (Ostarine) | Muscle Wasting | ~24 h | 3–20 | Recomp | Moderate | Moderate | Oral | None | Alternate name for Ostarine under clinical testing. | 7 |
| OPK-88003 | Muscle Wasting | ~20 h | 10–20 | Recomp | Moderate | Low | Oral | None | Being explored for catabolic conditions. | 5 |
| VBP-15 | Muscle Wasting | ~8 h | 5–15 | Anti-inflammatory | Low | None | Oral | None | Selective steroid receptor modulator, anti-inflammatory focus. | 4 |
| VK5211 (Enobosarm) | Muscle Wasting | ~36 h | 3–6 | Muscle Gain | Moderate | Low | Oral | None | Phase III clinical trials for muscle wasting. | 7 |
| YK-11 | Myostatin Inhibitor | ~6–8 h | 5–10 | Bulking | High | Low | Oral | None | Hybrid SARM/myostatin inhibitor, very anabolic. | 9 |
| AC-262536 | Recomp | ~6–12 h | 10–30 | Recomp | Moderate | Moderate | Oral | None | Lesser-known SARM, in early testing stages. | 6 |
| AC-0176 | Research | Unknown | 10–25 | Muscle Gain | Moderate | Low | Oral | None | Promising activity in murine models. | 5 |
| AMG-221 | Research | ~12 h | 10–25 | Muscle Gain | Moderate | Low | Oral | None | Potential for anabolic therapy applications. | 5 |
| AP-22408 | Research | ~6–8 h | 10–25 | Muscle Gain | Moderate | Low | Oral | None | In preclinical development for muscle enhancement. | 5 |
| BI-89000 | Research | ~6 h | 10–20 | Recomp | Moderate | Moderate | Oral | None | New compound under pharmaceutical development. | 5 |
| BMS-564929 | Research | ~8 h | 10–20 | Muscle Gain | Moderate | Low | Oral | None | Potent, highly selective SARM under investigation. | 6 |
| CP-262536 | Research | Unknown | 10–30 | Muscle Gain | Moderate | Low | Oral | None | Similar to AC-262536, minimal data available. | 5 |
| DSMO-14 | Research | Unknown | 10–30 | Muscle Gain | Moderate | Low | Oral | None | Limited data, still preclinical. | 5 |
| GS-9366 | Research | Unknown | 5–15 | Muscle Gain | Moderate | Unknown | Oral | None | Undergoing toxicity profiling. | 4 |
| GSX-108 | Research | ~8 h | 10–20 | Muscle Gain | Moderate | Low | Oral | None | Candidate for future preclinical trials. | 5 |
| JNJ-28330835 | Research | ~8 h | 10–30 | Muscle Gain | Moderate | Low | Oral | None | Investigational selective androgen modulator. | 6 |
| K-11706 | Research | ~6–10 h | 10–20 | Muscle Gain | Moderate | Low | Oral | None | Japanese compound in preclinical studies. | 5 |
| LG-120907 | Research | ~12 h | 10–30 | Recomp | Moderate | Low | Oral | None | Early SARM from Ligand Pharmaceuticals. | 5 |
| LG-121071 | Research | ~10 h | 5–15 | Cutting | Moderate | High | Oral | None | Reported to be highly selective and potent. | 6 |
| MK-0773 | Research | ~6 h | 10–30 | Recomp | Moderate | Low | Oral | None | SARM designed to avoid prostate effects. | 5 |
| PF-06260414 | Research | ~16 h | 5–15 | Recomp | Moderate | Moderate | Oral | None | Androgen receptor modulator, Pfizer candidate. | 6 |
| RTP-004 | Research | ~8 h | 5–20 | Recomp | Moderate | Low | Oral | None | Selective androgen receptor modulator. | 5 |
| SARM-4 | Research | Unknown | 10–30 | Muscle Gain | High | Moderate | Oral | None | Little human data; anecdotal high strength gains. | 5 |
| TSA-101 | Research | Unknown | 10–25 | Recomp | Moderate | Moderate | Oral | None | Synthetic androgen receptor modulator in development. | 6 |
| Tissue Selective AR Modulator-1 (TSAR-1) | Research | Unknown | 10–20 | Muscle Gain | Moderate | Low | Oral | None | Undergoing early-stage trials. | 5 |
| TDI-11861 | Spermatogenesis | ~10 h | N/A | Male Birth Control | None | None | Oral | None | Reversible male contraceptive in development. | 2 |
| SARM-X | Underground | ~8–12 h | 10–30 | Bulking | High | Moderate | Oral | None | Experimental blend on grey market. | 7 |
| SARM-Y | Underground | ~10 h | 10–30 | Cutting | Moderate | High | Oral | None | Unregulated mix circulating in fitness market. | 6 |
| SARM-Z | Underground | ~12 h | 10–20 | Recomp | Moderate | Moderate | Oral | None | Unofficial compound with mixed reports. | 6 |